Two New Drugs Show Promise in Doubling Survival for Pancreatic Cancer Patients
Recent clinical trials have revealed significant breakthroughs in pancreatic cancer treatment, with two new drugs demonstrating the potential to double patient survival rates. Revolution Medicines reported that its oral drug, daraxonrasib, extended average survival to 13.2 months compared to 6.7 months for standard chemotherapy in a Phase III trial. The company plans to seek expedited FDA approval, having received a National Priority Voucher. Simultaneously, Actuate Therapeutics published Phase II results in Nature Medicine showing that elraglusib, an intravenous treatment, also doubled one-year survival rates. These developments offer crucial hope for a disease where survival rates have plateaued despite historical improvements. Daraxonrasib targets KRAS mutations, present in over 90% of pancreatic tumors, marking a shift toward targeted therapy as a primary treatment backbone. Experts describe these findings as an inflection point in oncology, potentially changing standard care protocols. While immune-based therapies have previously struggled against pancreatic cancer, these targeted approaches address the root genetic causes. The medical community views these results as a foundational step toward more meaningful long-term benefits for patients across all stages of the disease.
Wire timeline
Two New Drugs Show Promise in Doubling Survival for Pancreatic Cancer Patients
Recent clinical trials have revealed significant breakthroughs in pancreatic cancer treatment, with two new drugs demonstrating the potential to double patient survival rates. Revolution Medicines reported that its oral drug, daraxonrasib, extended average survival to 13.2 months compared to 6.7 months for standard chemotherapy in a Phase III trial. The company plans to seek expedited FDA approval, having received a National Priority Voucher. Simultaneously, Actuate Therapeutics published Phase II results in Nature Medicine showing that elraglusib, an intravenous treatment, also doubled one-year survival rates. These developments offer crucial hope for a disease where survival rates have plateaued despite historical improvements. Daraxonrasib targets KRAS mutations, present in over 90% of pancreatic tumors, marking a shift toward targeted therapy as a primary treatment backbone. Experts describe these findings as an inflection point in oncology, potentially changing standard care protocols. While immune-based therapies have previously struggled against pancreatic cancer, these targeted approaches address the root genetic causes. The medical community views these results as a foundational step toward more meaningful long-term benefits for patients across all stages of the disease.
time